GlassScriptPhysician profile
Karinn L Gartmann
NPI 1578316600
$883.70
in general payments reported to CMS, 2019-2025
15 companies · $689 in 2025
The $689 reported for 2025 was more than what 79% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $194 · 2025: $689.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $884.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $883.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $199.80 | 2024-2025 | Fasenra, Farxiga, Airsupra |
| Lilly USA, LLC | $120.23 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Amgen INC. | $93.50 | 2024-2025 | Repatha, Repatha, Otezla |
| Novo Nordisk INC | $91.55 | 2025 | Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $77.18 | 2024-2025 | Trelegy Ellipta |
| Exact Sciences Corporation | $62.20 | 2025 | The Cologuard Plus Collection Kit |
| Corcept Therapeutics | $46.14 | 2025 | Korlym |
| Pfizer INC. | $40.64 | 2025 | |
| Lundbeck LLC | $26.75 | 2025 | Rexulti |
| Paratek Pharmaceuticals, INC. | $25.69 | 2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $25.69 | 2025 | Rexulti |
| Sanofi-Aventis U.S. LLC | $24.16 | 2025 | |
| Ardelyx, INC. | $19.11 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $17.49 | 2025 | |
| Sumitomo Pharma America, INC. | $13.57 | 2024 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karinn Gartmann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.